PMID- 31744308
OWN - NLM
STAT- MEDLINE
DCOM- 20200907
LR  - 20221207
IS  - 1542-6270 (Electronic)
IS  - 1060-0280 (Linking)
VI  - 54
IP  - 5
DP  - 2020 May
TI  - Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of 
      Type 2 Diabetes Mellitus.
PG  - 478-485
LID - 10.1177/1060028019889064 [doi]
AB  - Objective:The purpose of this article is to review the pharmacological 
      characteristics and clinical evidence of oral semaglutide for the treatment of 
      type 2 diabetes mellitus (T2DM). Data Sources: A MEDLINE/PubMed search was 
      conducted between January 1, 2005, and September 30, 2019. Search terms included 
      semaglutide, glucagon-like peptide 1 receptor agonist, GLP-1 receptor agonist, 
      and type 2 diabetes. Study Selection and Data Extraction Quantification: The 
      following study designs were included in the analysis: systematic review and/or 
      meta-analyses, clinical trial, or observational study design. Narrative reviews 
      were excluded. Articles were included only if they were published in the English 
      language or evaluated oral semaglutide with regard to pharmacology, 
      pharmacokinetics, safety, and efficacy in humans. Data Synthesis: Oral 
      semaglutide has been Food and Drug Administration approved for the treatment of 
      T2DM as an adjunct to diet and exercise. Oral semaglutide has been shown to 
      result in an absolute hemoglobin A(1C) reduction between -0.5% and -1.5% and 
      weight reductions between -1 and -4.7 kg. Oral semaglutide has been shown to be 
      noninferior to placebo for cardiovascular (CV) safety although additional CV 
      outcomes trials are ongoing. Adverse effects appear to be similar to those of 
      other glucagon-like peptide-1 receptor agonists and are gastrointestinal in 
      nature. Relevance to Patient Care and Clinical Practice: Oral semaglutide may be 
      appropriate as second- or third-line add-on therapy for patients with T2DM who 
      are not meeting treatment goals on metformin and are overweight and reluctant to 
      use an injectable drug. Conclusions: Oral semaglutide appears safe and effective 
      as monotherapy and add-on pharmacological therapy for the treatment of T2DM.
FAU - Cowart, Kevin
AU  - Cowart K
AUID- ORCID: 0000-0002-6880-1600
AD  - University of South Florida, Tampa, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191119
PL  - United States
TA  - Ann Pharmacother
JT  - The Annals of pharmacotherapy
JID - 9203131
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Administration, Oral
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Glucagon-Like Peptides/administration & dosage/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Metformin/therapeutic use
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - ambulatory care
OT  - antihyperglycemics
OT  - endocrinology
OT  - family medicine
OT  - type 2 diabetes
EDAT- 2019/11/21 06:00
MHDA- 2020/09/08 06:00
CRDT- 2019/11/21 06:00
PHST- 2019/11/21 06:00 [pubmed]
PHST- 2020/09/08 06:00 [medline]
PHST- 2019/11/21 06:00 [entrez]
AID - 10.1177/1060028019889064 [doi]
PST - ppublish
SO  - Ann Pharmacother. 2020 May;54(5):478-485. doi: 10.1177/1060028019889064. Epub 
      2019 Nov 19.